Stephen Chuan-Hao Kao

Author

Also Known As

Stephen Chuan-Hao Kao

Publications

332

Citations

H-Index

Concepts

All Affiliations

Stephen Chuan-Hao Kao is an author at Chris O’Brien Lifehouse specializing in oncology, cancer therapeutics, and molecular oncology.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	332
2	Health Sciences	3	3	126
3	Neurology	3	3	126
4	Pathology	3	3	126
5	Immunology	1	1	206

Stephen Chuan-Hao Kao

Publications

332

Citations

H-Index

Page 1

	Year	Citations
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. Hyun Cheol Chung, José A. López-Martín, Stephen Chuan-Hao Kao, Journal of Clinical Oncology Sclc PtsImmunologyImmunoeditingImmunotherapeuticsImmunotherapy	2018	206
Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study. James Chih‐Hsin Yang, Byoung Chul Cho, Dong‐Wan Kim, Journal of Clinical Oncology Leptomeningeal MetastasesPathologyNeuro-oncologyOncologyCerebrospinal Fluid	2017	94
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases. Myung‐Ju Ahn, Dong‐Wan Kim, Byoung Chul Cho, Journal of Clinical Oncology PathologyPharmacotherapyHigh-grade GliomasMetronomic ChemotherapyTumor Biology	2017	17
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy. Byoung Chul Cho, Myung‐Ju Ahn, Jong-Seok Lee, Journal of Clinical Oncology Cancer ManagementPathologyOther Anti-cancer TherapyPharmacotherapyHigh-grade Gliomas	2017	15

Page 1